Clinical Trial Search

Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 0; 4 days — p=<0.0001

Primary: Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) — 12; 6; 2; 0 Participants

Primary: Rate of Paclitaxel Treatment Completion Within 7 Weeks — 90 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 9; 9 Participants

Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction

Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants

Primary: Best Objective Response Evaluated According to the RECIST Criteria by Independent Review — 0; 0; 1; 1 Participants — p=0.7021

Primary: Percentage of Participants Admitted to the Hospital — 5.2; 1.7 percentage of participants

Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants

Primary: Exploratory: Percentage Change in IL-2 Production Relative to Pre-dose Values — -55.5 percentage of change in IL-2 production

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 17; 6 Participants

Primary: Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages — -60; -58; -53; -64 Percent (%)

Primary: Phase I: Recommended Phase II Dose (RPh2D) — 80 mg

Primary: Fasting Glucose — 6.1; 7.23; 6.48; 5.89 mmol/l

Primary: Change From Baseline in Intensity of Abdominal Pain Associated With Cramping Following Treatment Based on the Numeric Pain Rating Scale (NPRS) in Episode 1 — -2.7; -3.1…